Novocure (NVCR) Tops Q3 EPS by 7c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LEN
8. USO
9. LMT
10. AMZN

Go back to Novocure (NVCR) Tops Q3 EPS by 7c, Revenues Beat

Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update

October 31, 2019 6:00 AM EDT

Quarterly net revenues of $92.1 million, representing 42% growth versus the third quarter 2018

First quarter ever of positive net income with $0.02 in earnings per share

Continued clinical progress with four ongoing phase 3 pivotal trials creating the potential for substantial market expansion over the next five years

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the three and nine months ended September 30, 2019, highlighting strengthening financial performance, multiple levers to drive near-term growth and building momentum for the Tumor Treating Fields platform. Novocure is... More